Evaxion A/S Grants Warrants Potentially Exceeding Current Market Cap Value
EVAX has more than doubled off its 52-week low of $1.2 on light trading volume (0.1× avg).
Summary
Evaxion A/S granted over 9 million warrants to insiders and consultants with very low exercise prices, representing a potential value upon exercise greater than the company's current market capitalization.
Key Events · Financing and Capital Events · EVAX
-
Significant Warrant Grants
The company's board of directors granted an aggregate of 9,044,725 warrants in two tranches on February 5 and February 16, 2026.
-
Recipients Include Insiders and Consultants
Warrants were granted to board members, management, employees, and advisors/consultants.
-
Highly Favorable Exercise Prices
The warrants have exercise prices of $0.087 and $0.115 per ordinary share, significantly below the current stock price of $3.16.
-
Substantial Potential Dilution
If all warrants were exercised, it would result in a potential dilution of approximately 2.17% of the current outstanding shares. The implied value of the shares underlying these warrants, if exercised and sold at the current market price, would exceed the company's current market capitalization.
Analysis · EVAX · Life Sciences
The grant of 9,044,725 warrants to board members, management, employees, and consultants, with exercise prices of $0.087 and $0.115 per share, introduces substantial potential dilution. While the direct share dilution is approximately 2.17% of current outstanding shares, the implied value of these shares if exercised and sold at the current market price of $3.16 would exceed the company's entire market capitalization. This indicates a significant transfer of potential value to warrant holders, which is highly dilutive for existing shareholders. The low exercise prices make these warrants deeply in-the-money, providing a strong incentive for exercise.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVAX was trading at $3.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.5M. The 52-week trading range was $1.20 to $12.15. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.